Humedix Co Ltd (200670) - Total Liabilities

Latest as of September 2025: ₩23.40 Billion KRW ≈ $15.86 Million USD

Based on the latest financial reports, Humedix Co Ltd (200670) has total liabilities worth ₩23.40 Billion KRW (≈ $15.86 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Humedix Co Ltd - Total Liabilities Trend (2015–2024)

This chart illustrates how Humedix Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See Humedix Co Ltd working capital to net assets to evaluate short-term liquidity relative to the company's equity base.

Humedix Co Ltd Competitors by Total Liabilities

The table below lists competitors of Humedix Co Ltd ranked by their total liabilities.

Company Country Total Liabilities
S H Kelkar and Company Limited
NSE:SHK
India Rs14.75 Billion
Mulia Boga Raya PT
JK:KEJU
Indonesia Rp269.90 Billion
Maritime Resources Corp.
V:MAE
Canada CA$18.32 Million
Platinum Group Metals Ltd
TO:PTM
Canada CA$4.81 Million
SICHUAN ENG.INV.DEV.H YC1
F:84H
Germany €3.81 Billion
Skue Sparebank
OL:SKUE
Norway Nkr23.76 Billion
RCI Hospitality Holdings Inc
NASDAQ:RICK
USA $328.11 Million
Principal Capital Public Company Limited
BK:PRINC
Thailand ฿6.90 Billion

Liability Composition Analysis (2015–2024)

This chart breaks down Humedix Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Humedix Co Ltd (200670) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 9.22 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.09 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.08 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Humedix Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Humedix Co Ltd (2015–2024)

The table below shows the annual total liabilities of Humedix Co Ltd from 2015 to 2024.

Year Total Liabilities Change
2024-12-31 ₩21.22 Billion
≈ $14.38 Million
-3.17%
2023-12-31 ₩21.91 Billion
≈ $14.85 Million
-75.10%
2022-12-31 ₩88.03 Billion
≈ $59.65 Million
-2.05%
2021-12-31 ₩89.87 Billion
≈ $60.90 Million
+61.70%
2020-12-31 ₩55.58 Billion
≈ $37.67 Million
+111.18%
2019-12-31 ₩26.32 Billion
≈ $17.84 Million
+18.86%
2018-12-31 ₩22.14 Billion
≈ $15.00 Million
+1.46%
2017-12-31 ₩21.82 Billion
≈ $14.79 Million
-1.02%
2016-12-31 ₩22.05 Billion
≈ $14.94 Million
+261.59%
2015-12-31 ₩6.10 Billion
≈ $4.13 Million
--

About Humedix Co Ltd

KQ:200670 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$200.77 Million
₩296.25 Billion KRW
Market Cap Rank
#16640 Global
#636 in Korea
Share Price
₩28800.00
Change (1 day)
+1.77%
52-Week Range
₩24400.00 - ₩75800.00
All Time High
₩75800.00
About

Humedix Co., Ltd. engages in the manufacture and sale of various pharmaceutical products in South Korea. The company offers prescription medicines, active pharmaceutical ingredients, medical devices, cosmetics, and health functional food products. It is also involved in the manufacture and distribution of anticancer drugs. The company was formerly known as HVLS Co., Ltd. and changed its name to H… Read more